Testing a new skin inflammation treatment in healthy people and eczema patients

Plain-English translation of NCT07558668 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is an early-stage trial testing SYX-5219, a new experimental drug designed to treat atopic dermatitis (eczema). The study will first give the medication to healthy volunteers to make sure it is safe, then test it in people who actually have moderate to severe eczema. Researchers want to understand how safe the treatment is, how well people tolerate it, and how the body processes it.

Atopic dermatitis is a chronic skin condition that causes itching, redness, and inflammation, and many people don't respond well to current treatments. This trial is exploring whether this new medication could offer a better option for people struggling with moderate to severe eczema.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
for Part 3 (the eczema group): you have a clinical diagnosis of moderate to severe atopic dermatitis that covers at least 10% of your body surface area
for Part 3: your eczema causes significant itching (a score of 4 or higher on a standard itch scale)
you are in generally good health with no serious medical conditions (for Parts 1 and 2: healthy volunteers)
for female participants of childbearing potential: you are willing to practice sexual abstinence during the study

You likely don't qualify if…

you are currently taking prescription drugs, over-the-counter medications, vitamins, or herbal supplements (you would need to stop these before the study begins)
you have serious medical conditions or abnormal heart, blood, or vital sign measurements that your doctor thinks would put you at risk
you have recently received other targeted treatments for eczema
you have a BMI outside the acceptable range for the study

What participation looks like

If you join, you'll be randomly assigned to either receive the medication or a placebo (dummy pill). For the first two parts of the study (with healthy volunteers), you'll visit a UK clinic to receive single or multiple doses and have blood tests and vital signs checked. For the third part (with people who have eczema), you'll take the medication twice daily for up to 42 days at multiple sites around the world, with visits to assess your skin, measure itching, and monitor your safety.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Testing a new skin inflammation treatment in healthy people and eczema patients

What is this trial?

Do you qualify?

What participation looks like

Trial locations